Y-1693

N/A

Report date: 2024/12/20 13:45:41
NME

Base Information

Drug NameY-1693
Drug Alias NameY-1693
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShanghai Rui Jin Hospital
Inactive CompaniesN/A
Active IndicationsOsteoporosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A